Grants Archive - Sarcoma Foundation of America

Enhanced NK cell Immunotherapy for Treatment of Chemotherapy Refractory Sarcoma

July 9th, 2020

Daniel Vallera, PhD, University of Minnesota – Twin Cities

Recipient of the: $50,000 Dr. Richard and Valerie Aronsohn Memorial Research Award

Abstract: Radiation therapy is a crucial treatment modality required to control soft tissue and advanced bone sarcomas. Despite technological advancements used to treat radioresistant sarcomas, local recurrence and metastasis contin... Read More

MCL-1 inhibition unmasks BCL-2 addiction in synovial sarcoma

July 9th, 2020

Anthony Faber, PhD, Virginia Commonwealth University

Recipient of the: $50,000 Zach Cohen Memorial Research Award

Abstract: Metastatic Synovial Sarcoma (mSS) is frequently diagnosed in teenagers and young adults and continues to be treated with polychemotherapy with variable success. The SS18-SSX gene fusion is pathogenomic for the disease, and... Read More

Identification of novel drug targets and predictors of clinical outcomes in desmoplastic small round cell tumors using next-generation sequencing

July 9th, 2020

Madelyn Espinosa-Cotton, PhD, Memorial Sloan-Kettering Cancer Center

Recipient of the: $50,000 Zach Cohen Memorial Research Award

Abstract: Desmoplastic small round cell tumor (DSRCT) is a rare, highly-aggressive soft-tissue sarcoma with an overall five-year survival rate of less than 30%. Next generation sequencing (NGS) has given cancer researchers unprecede... Read More

Unraveling the tumor immune microenvironment of angiosarcomas

July 9th, 2020

Yvonne Versleijen-Jonkers, PhD, Radboud University Nijmegen Medical Center

Recipient of the: $50,000 Catherine Malatesta Memorial Research Award

Abstract: Is immune checkpoint inhibition the solution for angiosarcoma patients? Genetic and immune profiles of angiosarcoma subtypes will lead to novel insights for the design of individualized immune checkpoint-based therapy for ... Read More

Identifying mechanisms of osteosarcoma chemoresistance that arise from the lung metastatic niche

July 9th, 2020

Ryan Roberts, MD, PhD, The Research Institute at Nationwide Children’s Hospital

Recipient of the: $50,000 Pittsburgh Cure Sarcoma Research Award

Abstract: A therapy preventing the emergence of lung metastasis in adolescents with osteosarcoma could save more than 70% of the lives currently lost to this disease. This would represent the most significant improvement in outcome ... Read More

EWS-FLI1 triggered opportunistic de novo enhancer assembly activates potential cellular therapy targets in Ewing Sarcoma

July 9th, 2020

Irfan Asangani, PhD, University of Pennsylvania

Recipient of the: $50,000 STL Cure Sarcoma Research Award

Abstract: Ewings sarcoma is a rare type of cancerous tumor that grows in bones or the soft tissue around the bones, such as cartilage or the nerves. It usually affects children and young adults between the ages of 10 to 19. Ewings s... Read More

Evaluating the Chromatin Accessibility Landscape as a Driver of Clinical Behavior in Primary Treatment Naive Liposarcoma

July 9th, 2020

Emily Keung, MD, MD Anderson Cancer Center

Recipient of the: $50,000 STL Cure Sarcoma Research Award

Abstract: Liposarcomas are the most common histologies of soft tissue sarcomas. Although the most common subtypes of liposarcoma, well-differentiated liposarcoma (WDLPS) and dedifferentiated liposarcoma (DDLPS), often coexist, their... Read More

Unwinding new therapeutic opportunities in rhabdomyosarcoma: the role of RNA helicase DDX5

July 9th, 2020

Chiara Mozzetta, PhD, Istituto di Biologia e Patologia Molecolari

Recipient of the: $50,000 Race to Cure Sarcoma Research Award

Abstract: Rhabdomyosarcoma (RMS) is the most common soft-tissue sarcoma of childhood characterized by the inability to exit the proliferative myoblast-like stage. RMS can be divided in two main histopathological subtypes: alveolar (... Read More

Boosting Tumor Immunogenicity to Enhance Response to Immune Checkpoint Inhibitors in Soft Tissue Sarcomas

July 9th, 2020

Breelyn Wilky, MD, University of Colorado Cancer Center

Recipient of the: $50,000 Race to Cure Sarcoma Research Award

Abstract: Most soft tissue sarcomas (STS) remain incurable in the metastatic setting with traditional chemotherapy. Immune checkpoint inhibitors (ICIs), including antibodies to PD-1/PD-L1 and CTLA-4, act by reversing tumor-mediated ... Read More

Imaging response to CD47 mAb immunotherapy in pediatric patients with osteosarcoma

July 9th, 2020

Heike Daldrup-Link, MD, PhD, Stanford University

Recipient of the: $50,000 Race to Cure Sarcoma Research Award

Abstract: Children with metastatic bone cancer have a poor prognosis, with an overall survival rate of less than 30%. Stanford investigators developed a new drug, monoclonal antibodies against the cancer cell marker CD47 (CD mAb), w... Read More

Research Funded